The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Tagraxofusp (SL-401) in Patients With CMML or MF
Official Title: Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML) or Myelofibrosis (MF). [Prior Title: SL-401 in Patients With Advanced, High Risk Myeloproliferative Neoplasms (Systemic Mastocytosis, Advanced Symptomatic Primary Eosinophilic Disorder, Myelofibrosis, Chronic Myelomonocytic Leukemia).]
Study ID: NCT02268253
Brief Summary: This multi-center, multi-arm trial is evaluating the safety and efficacy of tagraxofusp, a CD123-targeted therapy, in patients with either chronic myelomonocytic leukemia (CMML) or myelofibrosis (MF). There are two CMML cohorts, one enrolling patients with CMML (CMML-1 or CMML-2) who are refractory/resistant or intolerant to hypomethylating agents (HMA), hydroxyurea (HU), or intensive chemotherapy; and one enrolling treatment-naive patients with CMML (CMML-1 or CMML-2) with molecular features associated with poor prognosis. The MF cohort will enroll patients who are resistant/refractory or intolerant to approved JAK therapy (JAK1/JAK2 or JAK2).
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
City of Hope, Duarte, California, United States
University of California, Los Angeles, Los Angeles, California, United States
University of Kansas Cancer Center, Westwood, Kansas, United States
Norton Cancer Institute, Louisville, Kentucky, United States
Mayo Clinic, Rochester, Minnesota, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Weill Cornell Medical Center, New York, New York, United States
MD Anderson Cancer Center, Houston, Texas, United States
University of Alberta, Edmonton, Alberta, Canada
Princess Margaret Cancer Centre, Toronto, Ontario, Canada